PT - JOURNAL ARTICLE AU - KAZUHISA NAKASHIMA AU - HIROAKI AKAMATSU AU - HARUYASU MURAKAMI AU - TAKASHI NIWA AU - YASUO IWAMOTO AU - YUICHI OZAWA AU - TOSHIHIDE YOKOYAMA AU - HIROYASU SHODA AU - NOBUYUKI YAMAMOTO AU - HIROSHIGE YOSHIOKA AU - KEN MASUDA AU - TATEAKI NAITO AU - KEITA MORI AU - TOSHIAKI TAKAHASHI TI - Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer AID - 10.21873/anticanres.13263 DP - 2019 Mar 01 TA - Anticancer Research PG - 1463--1468 VI - 39 IP - 3 4099 - http://ar.iiarjournals.org/content/39/3/1463.short 4100 - http://ar.iiarjournals.org/content/39/3/1463.full SO - Anticancer Res2019 Mar 01; 39 AB - Background/Aim: This phase I/II study aimed at assessing the efficacy of combination therapy with carboplatin (CBDCA) on day 1 and nab-paclitaxel (Nab-PTX) on days 1 and 8 of a 21-day cycle in performance status (PS) 2 patients with non-small-cell lung cancer (NSCLC). Patients and Methods: PS 2 patients with NSCLC were enrolled into a phase I study using a 3 + 3 design. Once the recommended phase II dose (RP2D) was established, the patients were enrolled into phase II. Results: Based on the phase I findings, the RP2D was determined as CBDCA area under the curve 6 mg/ml/min and Nab-PTX 100 mg/m2. In the phase II part, 27 patients were evaluable. The overall response rate was 44%. The median progression-free survival and overall survival were 5.2 months and 14.0 months, respectively. There was no treatment-related death. Conclusion: CBDCA plus Nab-PTX therapy is a promising treatment strategy for PS 2 patients with NSCLC.